INmune Bio Appoints Edgardo Baracchini to its Board of Directors, Gains Additional Licensing and Bus...

INmune Bio to Present at the BIO Investor 2017 Healthcare Conference...

INmune Bio Licenses INB03, a First-in Class Innate Immune System Check-Point Inhibitor that Targets ...

INmune Bio Licenses Technology to Deplete Myeloid Derived Suppressor Cells of the Innate Immune Syst...

INmune Bio Adds Clinical Development and Product Development Expertise with the Appointment of Tim S...

INmune Bio Co-Founder, Professor Mark Lowdell, Named One of Europe’s Academic-Entrepreneur Superst...